| Primary |
| Prophylaxis Against Graft Versus Host Disease |
15.9% |
| Stem Cell Transplant |
13.8% |
| Chronic Lymphocytic Leukaemia |
10.2% |
| Bone Marrow Conditioning Regimen |
9.4% |
| Product Used For Unknown Indication |
7.4% |
| Acute Myeloid Leukaemia |
7.3% |
| Infection Prophylaxis |
6.4% |
| Prophylaxis |
4.0% |
| Antifungal Prophylaxis |
3.6% |
| Myelodysplastic Syndrome |
2.9% |
| Acute Lymphocytic Leukaemia |
2.7% |
| Premedication |
2.4% |
| B-cell Lymphoma |
2.0% |
| Antibiotic Prophylaxis |
2.0% |
| Antiviral Prophylaxis |
1.8% |
| Cord Blood Transplant Therapy |
1.8% |
| Aplastic Anaemia |
1.7% |
| Drug Use For Unknown Indication |
1.7% |
| Platelet Transfusion |
1.5% |
| Packed Red Blood Cell Transfusion |
1.4% |
|
| Acute Graft Versus Host Disease |
13.7% |
| Sepsis |
8.7% |
| Chronic Graft Versus Host Disease |
8.1% |
| Graft Versus Host Disease |
6.0% |
| Infection |
5.9% |
| Venoocclusive Liver Disease |
5.2% |
| Death |
4.9% |
| Pyrexia |
4.6% |
| Thrombocytopenia |
4.6% |
| Respiratory Failure |
4.5% |
| Thrombotic Microangiopathy |
4.5% |
| Pneumonia |
4.3% |
| Neutropenia |
3.6% |
| Disease Progression |
3.5% |
| Pancytopenia |
3.5% |
| Renal Failure |
3.2% |
| Histiocytosis Haematophagic |
3.1% |
| Acute Graft Versus Host Disease In Skin |
2.8% |
| White Blood Cell Count Decreased |
2.8% |
| Febrile Neutropenia |
2.7% |
|
| Secondary |
| Chronic Lymphocytic Leukaemia |
14.3% |
| Product Used For Unknown Indication |
12.3% |
| Bone Marrow Conditioning Regimen |
11.6% |
| Prophylaxis Against Graft Versus Host Disease |
10.0% |
| Stem Cell Transplant |
8.5% |
| Prophylaxis |
6.6% |
| Infection Prophylaxis |
6.0% |
| Premedication |
3.7% |
| Acute Myeloid Leukaemia |
3.7% |
| Drug Use For Unknown Indication |
3.4% |
| Antifungal Prophylaxis |
3.3% |
| Immunosuppression |
2.2% |
| Antiviral Prophylaxis |
2.1% |
| Myelodysplastic Syndrome |
2.1% |
| Cord Blood Transplant Therapy |
1.9% |
| B-cell Lymphoma |
1.9% |
| Antibiotic Prophylaxis |
1.7% |
| Acute Lymphocytic Leukaemia |
1.7% |
| Hypertension |
1.5% |
| Aplastic Anaemia |
1.5% |
|
| Respiratory Failure |
8.8% |
| Acute Graft Versus Host Disease |
8.2% |
| Pyrexia |
7.7% |
| Myelodysplastic Syndrome |
6.6% |
| Febrile Neutropenia |
6.3% |
| Chronic Graft Versus Host Disease |
6.0% |
| Pneumonia |
5.8% |
| Sepsis |
5.6% |
| Thrombocytopenia |
4.8% |
| Progressive Multifocal Leukoencephalopathy |
4.7% |
| Neuroendocrine Carcinoma |
4.1% |
| Graft Versus Host Disease |
4.0% |
| Renal Failure Acute |
4.0% |
| Pulmonary Oedema |
3.8% |
| Urinary Tract Infection |
3.7% |
| Transplant Failure |
3.4% |
| Venoocclusive Liver Disease |
3.3% |
| Cognitive Disorder |
3.2% |
| Systemic Candida |
3.0% |
| Infection |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
17.8% |
| Infection Prophylaxis |
13.1% |
| Bone Marrow Conditioning Regimen |
12.2% |
| Prophylaxis |
10.5% |
| Prophylaxis Against Graft Versus Host Disease |
9.5% |
| Premedication |
4.6% |
| Chronic Lymphocytic Leukaemia |
4.1% |
| Antifungal Prophylaxis |
3.8% |
| Immunosuppression |
3.6% |
| Acute Lymphocytic Leukaemia |
2.5% |
| Allogenic Bone Marrow Transplantation Therapy |
2.4% |
| Acute Myeloid Leukaemia |
2.4% |
| Stem Cell Transplant |
2.4% |
| B-cell Lymphoma |
2.1% |
| Antiviral Prophylaxis |
1.9% |
| Prophylaxis Of Nausea And Vomiting |
1.6% |
| Drug Use For Unknown Indication |
1.4% |
| Graft Versus Host Disease |
1.4% |
| Non-hodgkin's Lymphoma |
1.4% |
| Hypertension |
1.3% |
|
| Thrombotic Microangiopathy |
15.7% |
| Pyrexia |
7.6% |
| Sepsis |
7.6% |
| White Blood Cell Count Decreased |
7.6% |
| Acute Graft Versus Host Disease |
7.0% |
| Drug Ineffective |
5.4% |
| Progressive Multifocal Leukoencephalopathy |
5.4% |
| Death |
4.9% |
| Staphylococcal Sepsis |
4.3% |
| Thrombocytopenia |
3.8% |
| Acute Graft Versus Host Disease In Skin |
3.2% |
| Disseminated Intravascular Coagulation |
3.2% |
| Multi-organ Failure |
3.2% |
| Platelet Count Decreased |
3.2% |
| Renal Failure Acute |
3.2% |
| Urinary Tract Infection |
3.2% |
| Venoocclusive Liver Disease |
3.2% |
| Cystitis Haemorrhagic |
2.7% |
| Lung Infection |
2.7% |
| Myelodysplastic Syndrome |
2.7% |
|
| Interacting |
| Acute Myeloid Leukaemia |
100.0% |
|
| Pulmonary Haemorrhage |
100.0% |
|
